Login to Your Account

Competition Getting 'Fierce'

Lower-Priced Eylea Taking on Lucentis in Growing AMD Space

By Jennifer Boggs
Managing Editor

Tuesday, November 22, 2011
Regeneron Pharmaceuticals Inc.'s Eylea (aflibercept) hits the market this week, and analysts are looking to its less frequent dosing schedule and lower cost to nab a substantial portion of the market from Roche AG's reigning VEGF inhibitors – Lucentis (ranibizumab) and cheaper off-label cancer drug Avastin (bevacizumab) – in wet age-related macular degeneration (AMD).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription